Annals of Hematology

, Volume 89, Supplement 1, pp 19–23

Future research in ITP: an ICIS consensus

  • James L. Zehnder
  • John W. Semple
  • Paul Imbach
  • Ellis J. Neufeld
  • George R. Buchanan
  • Douglas B. Cines
  • ICIS Study Group on Future Research in ITP
Future Research

Abstract

While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and optimize use of existing therapies. The answers to these questions are likely to impact our understanding of the pathogenesis and therapeutic targets of autoimmune disease in general.

Keywords

Immune thrombocytopenia ITP Autoimmune diseases 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • James L. Zehnder
    • 1
  • John W. Semple
    • 2
  • Paul Imbach
    • 3
  • Ellis J. Neufeld
    • 4
  • George R. Buchanan
    • 5
  • Douglas B. Cines
    • 6
  • ICIS Study Group on Future Research in ITP
  1. 1.Department of PathologyStanford University School of MedicineStanfordUSA
  2. 2.Department of PharmacologyUniversity of TorontoTorontoCanada 
  3. 3.Department of PediatricsUniversity of BaselBaselSwitzerland 
  4. 4.Department of Pediatric HematologyHarvard Medical SchoolBostonUSA 
  5. 5.Department of PediatricsUniversity of Texas Southwestern Medical Center at DallasDallasUSA
  6. 6.Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphia USA

Personalised recommendations